Kashiv BioSciences
Biosimilar developer, United States. 2 development products across 2 molecules: filgrastim, pegfilgrastim.
First approval in the Atlas: Feb 2022, Releuko, filgrastim (FDA)
FDAproducts approved2
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Filgrastim | Releuko | Feb 2022 | · | · | · | · | · |
| Pegfilgrastim | Fylnetra | May 2022 | · | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- FDAFeb 2022Releuko, filgrastim
- FDAMay 2022Fylnetra, pegfilgrastim
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.